Heart failure 25 items
Studies
- Lp(a) molar concentration, not apo(a) size, drives cardiovascular risk; loss of Lp(a) raises diabetes risk: deCODE (Gudbjartsson et al., JACC 2019)J Am Coll Cardiol · December 2019 8
- The phenotypic consequences of genetically lowered Lp(a) (Emdin et al., JACC 2016)J Am Coll Cardiol · December 2016 8
- Lp(a) lowering by alirocumab reduces total cardiovascular events independent of LDL-C: ODYSSEY OUTCOMES (Szarek et al., EHJ 2020)Eur Heart J · November 2020 7
- PREVENT equations perform well but Lp(a) adds independent risk, most in borderline- and low-risk people: MESA and UK Biobank (Bhatia et al., JAMA Cardiol 2025)JAMA Cardiol · August 2025 6
- Sex differences in Lp(a) levels and associated risk by age: Copenhagen (Simony et al., Atherosclerosis 2022)Atherosclerosis · August 2022 6
- Elevated Lp(a) and LPA risk genotypes raise the risk of heart failure (Kamstrup and Nordestgaard, JACC Heart Fail 2016)JACC Heart Fail · January 2016 6
- Lp(a) and family history of cardiovascular disease combine to raise heart failure risk by 42% in 299,158 UK Biobank adults (J Lipid Res 2023)J Lipid Res · June 2023 8
- Lp(a) raises heart failure risk in white participants only, not in Black, Hispanic or Chinese participants, the MESA study of 6,809 adults (Arterioscler Thromb Vasc Biol 2018)Arterioscler Thromb Vasc Biol · October 2018 8
- Lp(a) raises heart failure risk in a nonlinear, plateauing dose-response pattern, meta-analysis of 400,631 (Clin Cardiol 2026)Clin Cardiol · April 2026 7
- Lp(a) and LDL-C synergistically raise MI risk, amplified by polygenic risk score, UK Biobank cohort of 346,751 (Am J Cardiol 2026)Am J Cardiol · September 2025 7
- Elevated Lp(a) predicts heart failure in White but not Black participants, pooled 16,771-person ARIC/MESA/FOS analysis finds, largely via prior heart attack (J Am Heart Assoc 2025)J Am Heart Assoc · May 2025 7
- Lp(a) 30 mg/dL or more predicts cardiovascular death or HF hospitalization, cohort of 1,088 (J Card Fail 2026)J Card Fail · April 2025 7
- Higher Lp(a) tertile independently predicts MACE in 399 patients with heart attack complicated by preserved-ejection-fraction heart failure (Front Cardiovasc Med 2025)Front Cardiovasc Med · January 2025 7
- CASABLANCA study finds Lp(a) above 150 nmol/L nearly doubles the risk of stage A/B heart failure progressing to symptomatic disease (J Am Heart Assoc 2024)J Am Heart Assoc · June 2024 7
- Elevated Lp(a) is linked to subclinical myocardial fibrosis and left atrial remodelling in 2,826 MESA participants (J Am Coll Cardiol 2023)J Am Coll Cardiol · December 2023 7
- Lp(a) predicts heart failure hospitalization, but the link disappears once prior heart attacks are excluded, the ARIC study of 14,154 adults (Atherosclerosis 2017)Atherosclerosis · May 2017 7
- Lp(a) drives coronary microvascular dysfunction via antifibrinolytic and oxidised-phospholipid pathways, review (Life Sci 2026)Life Sci · April 2026 6
- Meta-analysis of seven Mendelian randomisation studies confirms Lp(a) causally raises heart failure risk (Curr Probl Cardiol 2024)Curr Probl Cardiol · January 2024 6
- Lp(a) risk rises above 30 mg/dL, with the accepted 50 mg/dL threshold, and levels can range beyond 1000 mg/dL, a pathophysiology and treatment review (Int J Environ Res Public Health 2023)Int J Environ Res Public Health · September 2023 6
- Elevated Lp(a) shows a consistent positive association with heart failure across 73,410 patients in 8 studies, a systematic review (Heart Fail Rev 2023)Heart Fail Rev · July 2023 6
- Despite ESC guidance, Lp(a) was measured in only a third of STEMI and 15% of NSTEMI patients, and showed no link to heart failure markers, Luebeck registry finds (Atheroscler Plus 2025)Atheroscler Plus · July 2025 5
- Elevated Lp(a) tracks with cardiac MRI signs of myocardial fibrosis in group II pulmonary hypertension from HFpEF (Future Cardiol 2025)Future Cardiol · February 2025 5
- Mendelian randomisation confirms Lp(a) drives coronary disease, aortic stenosis, stroke and heart failure regardless of LDL control, a review revisiting two decades of evidence (Circ J 2020)Circ J · April 2020 5
- Impact of hypertension on associations of all-cause mortality with admission lipoprotein (a) in acute decompensated heart failureInt J Cardiol Cardiovasc Risk Prev · June 2026 4
- At a Bronx safety-net hospital, elevated Lp(a) tracked with HFpEF and higher LDL but not with other ASCVD risk factors in 78 tested patients (Heart Views 2025)Heart Views · January 2025 4